In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Drug-Coated Balloons Market Report
The drug-coated balloons market by revenue is expected to grow at a CAGR of 15% during the period 2019–2025.
The global drug-coated balloons market is one of the fastest-growing segments in the cardiovascular devices market. The market is growing significantly due to the surge in incidence/prevalence of cardiovascular diseases, especially peripheral artery and coronary artery diseases across the globe.
The COVID-19 pandemic is likely to profoundly affect the drug-coated balloons market in several countries across the globe. With the spread of the pandemic, several hospitals, CATH labs, and ASCs have experienced a rapid decline in the volume of elective cardiology procedures. Although COVID-19 is a global pandemic, some countries have experienced a higher incidence of the virus than others.
The following factors are likely to contribute to the growth of the the drug-coated balloons market during the forecast period: • Expanding Indications of Drug-Coated Balloons • Emergence of Latest Generation DCBs • Growth in Target Patient Pool across the Globe
The study considers the present scenario of the drug-coated balloons devices market and its market dynamics for the period 2019?2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspect of the market. It profiles and examines leading companies and other prominent ones operating in the market.
Global Drug-Coated Balloons Market Segmentation The global drug-coated balloons market research report includes a detailed segmentation by indication, drug type, end-user, geography. The peripheral artery disease (PAD) segment accounted for a share of over 81% in 2019, and it is expected to retain its market dominance during the forecast period. The adoption of drug-coated balloons (DCB) for treating PAD is growing rapidly, primarily due to the availability of positive clinical data, supporting the safety and efficacy of DCB technology. The segment accounts for the largest share as the majority of DCB devices are commercially available for PAD indication. However, despite high potential growth opportunities for treating PAD, the recent COVID-19 pandemic has caused unprecedented challenges to perform PCI procedures. The spread of the virus has triggered disruption across the globe with lockdowns, travel bans, and ban on large gatherings such as major cardiac scientific society meetings being canceled, with substantial pressure on the health care services across the world.
The paclitaxel segment accounts for the maximum market share as these devices are safe and effective in treating CVDs, AV, and urological disorders. Paclitaxel-coated balloon (PCB) technology has emerged as a promising therapeutic alternative in the PCI procedure, especially for CVDs. The majority of commercially available DCBs are paclitaxel-coated. Paclitaxel-coated balloons are clinically proven, reducing the risk of restenosis after angioplasty of atherosclerotic femoropopliteal lesions. This is increasing their demand among healthcare professionals. In 2019, the sirolimus segment accounted for over 3% of the market. This segment is a new generation of DCBs, where balloons are coated with a medicine called sirolimus. There are a few commercially available sirolimus DCBs. Thus the contribution of the segment is low than paclitaxel-coated balloons.
The global drug-coated balloons market is segmented into hospitals, freestanding CATH labs, and ASCs. Healthcare professionals in hospitals use DCBs mainly for cardiovascular disorders, including AV interventions, urological, and neurovascular procedures. The segment is growing at a healthy rate due to the high adoption of the latest generation DCBs. A majority of patients with an increased risk of cardiovascular diseases prefer visiting hospitals for treatment due to advanced infrastructure facilities available in major private and public hospitals, the segment is expected to grow significantly.
By Indication • PAD • CAD • Others By Drug Type • Paclitaxel • Sirolimus By End-user • Hospitals • Ambulatory Care Settings • Freestanding Cath Labs
INSIGHTS BY GEOGRAPHY North America occupies a dominant position in the global drug-coated balloons market. The presence of a large disease population, coupled with better access to treatment, is the primary factor for the high market share. The market in North America is expected to witness lucrative growth during the forecast period due to expanded indication approvals for commercialized DCBs, new product approvals, and the availability of abundant clinical evidence.
By Geography • North America o US o Canada • Europe o UK o Germany o France o Italy o Spain • APAC o China o Japan o South Korea o India o Australia • Latin America o Brazil o Mexico o Argentina • Middle East & Africa o Saudi Arabia o Turkey o South Africa o Israel
INSIGHTS BY VENDORS The global drug-coated balloons market is highly dynamic with the presence of global, regional, and local players offering a broad range of latest-generation DCBs for end-users. Medtronic, BD, Koninklijke Philips, Boston Scientific, and B. Braun Melsungen are the key vendors in the market in terms of technology, safety features, regulatory approvals, marketing strategies, and distribution channels.
Prominent Vendors • Medtronic • BD • Koninklijke Philips • Boston Scientific • B. Braun Melsungen
Other Prominent Vendors • Aachen Resonance • Acotec Scientific • AR Baltic Medical • Biosensors International Group • BIOTRONIK • Cardionovum • Concept Medical • eucatech • ENDOCOR • HEXACATH • iVascular • M.A. Med Alliance • Meril Life Sciences • Nano Therapeutics • QT Vascular • RD Global-Invamed • STENTYS • Surmodics • Terumo • Urotronic • Wellinq
KEY QUESTIONS ANSWERED 1. What is the drug-coated balloons market size and growth rate during the forecast period? 2. What are the factors impacting the growth of the drug-coated balloons market share? 3. What is the growth of North America drug-coated balloons market during the forecast period? 4. Who are the leading vendors in the drug-coated balloons market? 5. What is the impact of COVID-19 pandemic on the global market?
Our reports have been used by over 10K customers, including:
Transthyretin - Pipeline Review, H2 2020 Summary According to the recently published report ’Transthyretin - Pipeline Review, H2 2020’; Transthyretin (ATTR or Prealbumin or TBPA or TTR) pipeline Target constitutes close to 16 molecules. Out of which approximately 14 molecules are developed by companies...
Congenital Heart Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Congenital Heart Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Congenital Heart Disease Clinical trials scenario.This report provides top line data relating to the clinical...
Brazil Clot Management Devices Market Outlook to 2025 - CDT Catheters, Embolectomy Balloon Catheters, Inferior Vena Cava Filters (IVCF) and Others Summary “Brazil Clot Management Devices Market Outlook to 2025” is a comprehensive databook report, covering key market data on the Brazil Clot Management...
Cardiovascular Surgery Devices - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Cardiovascular Surgery Devices - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Cardiovascular Surgery Devices pipeline products with comparative...
Soluble Guanylate Cyclase - Pipeline Review, H2 2020 Summary Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The latest report Soluble...
The North America neurovascular devices market is expected to reach US$ 1389.28 million by 2027 from US$ 1,004.75 million in 2019. The market is estimated to grow at a CAGR of 4.2% during the forecast period. Key factors that are driving the North America neurovascular devices market are increasing incidence of neurovascular diseases, rising...
Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020 Summary According to the recently published report ’Cholesteryl Ester Transfer Protein - Pipeline Review, H2 2020’; Cholesteryl Ester Transfer Protein (Lipid Transfer Protein I or CETP) pipeline Target constitutes close to 7 molecules....
Global Autoimmune Partnering 2014 to 2020 provides the full collection of Autoimmune disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Autoimmune partnering deals Financial deal terms for headline, upfront and royalty by stage of development Autoimmune partnering...
Arrhythmias Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Arrhythmias Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Arrhythmias Clinical trials scenario. This report provides top line data relating to the clinical trials on Arrhythmias....
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.